Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Genes Brain Behav ; 2(6): 350-64, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14653307

RESUMEN

Current evidence indicates that virtually all neuropsychiatric disorders, like many other common medical disorders, are genetically complex, with combined influences from multiple interacting genes, as well as from the environment. However, additive or epistatic gene interactions have proved quite difficult to detect and evaluate in human studies. Mouse phenotypes, including behaviors and drug responses, can provide relevant models for human disorders. Studies of gene-gene interactions in mice could thus help efforts to understand the molecular genetic bases of complex human disorders. The serotonin transporter (SERT, 5-HTT, SLC6A4) provides a relevant model for studying such interactions for several reasons: human variants in SERT have been associated with several neuropsychiatric and other medical disorders and quantitative traits; SERT blockers are effective treatments for a number of neuropsychiatric disorders; there is a good initial understanding of the phenotypic features of heterozygous and homozygous SERT knockout mice; and there is an expanding understanding of the interactions between variations in SERT expression and variations in the expression of a number of other genes of interest for neuropsychiatry and neuropharmacology. This paper provides examples of experimentally-obtained interactions between quantitative variations in SERT gene expression and variations in the expression of five other mouse genes: DAT, NET, MAOA, 5-HT(1B) and BDNF. In humans, all six of these genes possess polymorphisms that have been independently investigated as candidates for neuropsychiatric and other disorders in a total of > 500 reports. In the experimental studies in mice reviewed here, gene-gene interactions resulted in either synergistic, antagonistic (including 'rescue' or 'complementation') or more complex, quantitative alterations. These were identified in comparisons of the behavioral, physiological and neurochemical phenotypes of wildtype mice vs. mice with single allele or single gene targeted disruptions and mice with partial or complete disruptions of multiple genes. Several of the descriptive phenotypes could be best understood on the basis of intermediate, quantitative alterations such as brain serotonin differences. We discuss the ways in which these interactions could provide models for studies of gene-gene interactions in complex human neuropsychiatric and other disorders to which SERT may contribute, including developmental disorders, obesity, polysubstance abuse and others.


Asunto(s)
Proteínas Portadoras/genética , Modelos Animales de Enfermedad , Ambiente , Regulación de la Expresión Génica/genética , Glicoproteínas de Membrana/genética , Trastornos Mentales/genética , Proteínas del Tejido Nervioso/genética , Animales , Conducta Animal/fisiología , Factor Neurotrófico Derivado del Encéfalo/genética , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Humanos , Proteínas de Transporte de Membrana/genética , Ratones , Ratones Noqueados , Ratones Mutantes , Ratones Transgénicos , Monoaminooxidasa/genética , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática , Sitios de Carácter Cuantitativo/genética , Receptor de Serotonina 5-HT1B/genética , Serotonina/genética , Proteínas de Transporte de Serotonina en la Membrana Plasmática , Simportadores/genética
3.
Mol Psychiatry ; 12(10): 946-57, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17440436

RESUMEN

Neuregulin1 (NRG1), a candidate susceptibility gene for schizophrenia, plays a critical role in neuronal migration and central nervous system development. However, its relation to schizophrenia pathogenesis is unknown. Here we show that B lymphoblasts migrate to NRG1 through the ErbB-signaling system as observed in neuronal cells. We assessed NRG1-induced cell migration in B lymphoblasts from patients with schizophrenia and found that NRG1-induced migration is significantly decreased compared with control individuals in two independent cohorts. This impaired migration is related at least in part to reduced AKT phosphorylation in the patients. Moreover, the magnitude of NRG1-induced migration is associated with polymorphisms of the NRG1 and catechol-o-methyltransferase genes and with an epistatic interaction of these genes. This study demonstrates that the migratory response of schizophrenia-derived cells to NRG1 is impaired and is associated with genetic variations in more than one schizophrenia susceptibility gene, providing a novel insight into potential neurodevelopmental mechanisms of schizophrenia.


Asunto(s)
Linfocitos B/efectos de los fármacos , Catecol O-Metiltransferasa/genética , Movimiento Celular/efectos de los fármacos , Neurregulina-1/genética , Neurregulina-1/farmacología , Polimorfismo Genético/efectos de los fármacos , Esquizofrenia/patología , Adulto , Análisis de Varianza , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Quimiotaxis/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Receptor ErbB-2/metabolismo , Receptor ErbB-3/metabolismo , Esquizofrenia/genética , Transducción de Señal/efectos de los fármacos , Estadísticas no Paramétricas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA